30 September 2024
The Russian Ministry of Health has announced the registration of Russia’s first bioanalogue of the Swiss medication “Actemra” (tocilizumab, Roche), developed by the company “Generium,” for the treatment of rheumatoid arthritis. The trade name of the domestic drug is “Complarate”.
This medication is designed to mitigate systemic inflammatory responses and is utilized in the treatment of rheumatoid arthritis, including systemic juvenile idiopathic arthritis. It is also effective in addressing severe COVID-19 cases and life-threatening cytokine release syndrome.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Enhancing spectroscopy analysis with machine learning
03 February 2025
The production of new Russian “super antibiotic” to begin in Novosibirsk
03 February 2025
A Russian company has started producing 4 veterinary vaccines
31 January 2025
The government held its first meeting on the “New technologies for preserving health” project
31 January 2025